Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:IRMD

iRadimed Q3 2026 Earnings Date & Estimates

iRadimed logo
$89.83 +0.18 (+0.20%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

iRadimed is estimated to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. The conference call is scheduled for 11:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
11:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from iRadimed in Q3 2026

iRadimed is expected to post earnings of $0.55 per share on revenue of $23.47 million. In the same quarter a year earlier iRadimed reported $0.47 per share on revenue of $21.20 million. iRadimed last reported on July 31, 2026, posting $0.46 per share and beating the $0.44 consensus estimate. iRadimed has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.55
Expected Revenue
$23.47 million
Prior-Year EPS
$0.47
Prior-Year Revenue
$21.20 million
Expected EPS Growth
+17.0%
Expected Revenue Growth
+10.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.46 (Beat by +$0.02)
Last Quarter Revenue
$20.47 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

iRadimed Q3 2026 Earnings FAQ

iRadimed (NASDAQ:IRMD) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

iRadimed's Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 11:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect iRadimed to post earnings of $0.55 per share for Q3 2026.

The consensus revenue estimate for iRadimed is $23.47 million for Q3 2026.

iRadimed Earnings Headlines

Head to Head Contrast: PROCEPT BioRobotics (NASDAQ:PRCT) vs. iRadimed (NASDAQ:IRMD)
October 12 at 10:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110886
iRadimed (NASDAQ:IRMD) Stock Price Breaks Above 50 Day Moving Average - Here's Why
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102314
Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367510/32443/en/iradimed-corporation-to-participate-in-the-5th-annual-roth-healthcare-opportunities-conference.html
Needham Initiates IRadimed at Hold
September 22, 2026  |  marketscreener.comM
iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100
September 4, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9069044/iradimed-corp-irmd-stock-down-38-but-still-overvalued-gf-score-92100
See More iRadimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRadimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRadimed and other key companies, straight to your email.

About iRadimed

iRadimed (NASDAQ:IRMD) develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.

Its products include the MRidium MRI-compatible infusion pump system, which is designed to deliver intravenous medications and fluids without interfering with MRI operations, and MRI-compatible patient-monitoring systems used to track vital signs during imaging. The company also offers related accessories, disposables, service and support.

Founded in 2004 and headquartered in Winter Park, Florida, IRadimed sells its products to hospitals and other healthcare providers in the United States and international markets through a combination of direct sales and distributors. Roger Susi has served as the company’s president and chief executive officer and is among its longtime leaders.

View iRadimed Profile
Earnings Tools